Bevacizumab is an FDA-approved anti-VEGF-A antibody that prevents receptor binding and has effectively been used in various cancers, including colorectal cancer, lung cancer, and epithelial ovarian cancer [7,15,19,20]. Here, VEGFA is linked to ovarian carcinoma.